Hypertension is a new Decision Resources study that explains why the seemingly saturated hypertension market remains open to innovation and, based on thought-leader opinion and insight, assesses the therapeutic and commercial potential of emerging agents in this sector.
Emerging therapies for hypertension fall into three distinct classes: new agents in an established class, new agents in a novel class, and single-pill combinations of existing drugs.
Physicians interviewed were not enthusiastic about the prospect for new agents in the well-established classes, such as angiotensin converting enzyme inhibitors (ACEIs) and calcium-channel blockers (CCBs). New agents launched in these markets will face daunting barriers unless they are supported by substantial clinical trial evidence that proves their superiority to physicians' current drug choices. Within this sector, angiotensin II receptor antagonists (AIIRAs) are poised to take market share from currently available antihypertensive agents because of their superior side-effect profiles and because they have the potential to be used instead of ACEIs and in combination with other antihypertensive agents.
New agents in novel classes of drugs will also face barriers to market entry. Their success will depend on physician opinion of the agents and of the novel mechanisms of action. Physicians we interviewed are enthusiastic about new agents with novel pharmacological action -- for example, single molecules with dual activities, like omapatrilat (Bristol-Myers Squibb's Vanlev), that generate multiple antihypertensive actions simultaneously. Interestingly, physicians are also enthusiastic about novel agents (endothelin antagonists, for instance) that are not aimed specifically at hypertension but address some aspects of hypertension as they are viewed within the wider realm of vascular disease.
Perhaps the most surprising fact in the area of emerging therapies for hypertension is that physicians are greatly interested in new fixed-pill combinations of currently available drugs. Physicians interviewed state that combination therapies confer extra antihypertensive benefit, encourage patient compliance, and facilitate prescription of multidrug regimens. However, few novel combinations are being developed. Considering the range of drugs now used as first- and second-line therapies, it seems likely that combinations of these agents would offer many more possibilities than those now in development.
Hypertension offers invaluable market intelligence for firms competing in this arena. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or email@example.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or firstname.lastname@example.org. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or email@example.com.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, +1-781-296-2553, or